Todd Asset Management LLC Has $974,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Todd Asset Management LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 95.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,023 shares of the biopharmaceutical company's stock after selling 273,340 shares during the period. Todd Asset Management LLC's holdings in Gilead Sciences were worth $974,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Tompkins Financial Corp grew its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $29,000. Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $33,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $40,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.55 during trading on Friday, hitting $64.78. 7,822,720 shares of the stock were exchanged, compared to its average volume of 7,345,331. The company has a market cap of $80.66 billion, a PE ratio of 179.94, a P/E/G ratio of 1.31 and a beta of 0.22. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. The company has a fifty day moving average price of $70.55 and a two-hundred day moving average price of $75.83. Gilead Sciences, Inc. has a 12-month low of $64.33 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the business earned $1.37 earnings per share. Gilead Sciences's quarterly revenue was up 5.3% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.75%. Gilead Sciences's dividend payout ratio (DPR) is currently 855.56%.

Analyst Ratings Changes

Several equities analysts recently issued reports on GILD shares. Oppenheimer restated an "outperform" rating and issued a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Friday, April 26th. Truist Financial lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating and lowered their price objective for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Maxim Group dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a "neutral" rating for the company in a research note on Wednesday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $83.69.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.